We also found TCP1 to be predicted in mastocytosis and B-cell precursor-ALL, whose high expression has been associated with AML drug resistance and poor survival through the activation of AKT/mTOR signaling [98]. The gene discussed is MTOR; the disease is acute myeloid leukemia.